
References

- Abreu MT, Arditi M.** Innate immunity and toll-like receptors: clinical implications of basic science research. *J Pediatr.* 2004; 144: 421-429.
- Adriana GO, Maria das GPS, Gifone AR, Andreia MCR, Adriana S, Renato D, Frederico PM, Liano SM, Maria de LAF, Silvia, BM, Lucia PFC and Dulciene MMQ.** *Helicobacter* species in the intestinal mucosa of patients with ulcerative colitis. *J of Clinical Microbiology* 2004; 42: 1, 384-386.
- Aguejof O, Mayo K, Monteiro L, Doutremepuich F, Doutremepuich C, Megraud F.** Increase of arterial thrombosis parameters in chronic *Helicobacter pylori* infection in mice. *Thromb Res* 2002;108:245–248.
- Ahluwalia C, Jain M, Mehta G, Kumar N.** Comparison of endoscopic brush cytology with biopsy for the detection of *Helicobacter pylori* in patients with gastroduodenal disease. *Indian J Pathol Microbiol* 2001; 44: 283–288.
- Ahmad T, Satsangi J, McGovern D, Bunce M, Jewell DP.** Review article: the genetics of inflammatory bowel disease. *Alimentary Pharmacology&Therapeutics.* 2001;15:731-748.
- Al-Eiden FA, McElnay JC, Scott MG, McConnell JB.** Management of *H. pylori* eradication. *Alimentary Pharmacology & Therapeutics* 2003; 17: 89–97
- Ananieva O, Nilsson I, Vorobjova T, Uibo R, Wadstrom T.** Immune responses to bile-tolerant *Helicobacter* species in patients with chronic liver diseases, a randomized population group, and healthy blood donors. *Clin Diagn Lab Immunol* 2002; 9: 1160–1164.
- Annibale B, Capurso G, Lahner E, et al.** Concomitant alterations in intragastric pH and ascorbic acid concentration in patients with *Helicobacter pylori* gastritis and associated iron deficiency anaemia. *Gut* 2003;52:496–501.

- Armuzzi A, De Pascalis B, Lupascu A, Fedeli P, Leo D, Mentella MC, et al.** Infliximab in the treatment of steroid-dependent ulcerative colitis. *Eur Rev Med Pharmacol Sci.*2004;8:231-233
- Arnott ID, Landers CJ, Nimmo EJ, Drummond HE, Smith BK, Targan SR, et al.** Sero-reactivity to microbial components in Crohn's disease is associated with disease severity and progression, but not NOD2/CARD15 genotype. *Am J Gastroenterol.* 2004;99:2376-2384.
- Auer J, Berent R, Weber T, Eber B.** *Helicobacter pylori* infection, infectious burden, and coronary artery disease. *Am J Cardiol* 2002;90:87.
- Babic T, Basic H, Miljkovic B, Kocic B, Tasic G.** Detection of *H. pylori* in gasteric biopsy and resection specimens. *Vojnosanit Pregl.* 2005;62:39-43.
- Bagis T, Gumurdulu Y, Kayaselcuk F, Yilmaz ES, Kilicadag E, Tarim E.** Endoscopy in hyperemesis gravidarum and *Helicobacter pylori* infection. *In J Gynecol Obstet* 2002;79:105–109.
- Bamias G, Martin C 3rd, Marini M, Hoang S, Mishina M, Ross WG, et al.** Expression, localization, and functional activity of TL1A, a novel Th1-polarizing cytokine in inflammatory bowel disease. *J Immunol.* 2003;171:4868-4874.
- Bamias G, Martin C, Mishina M, Ross WG, Rivera-Nieves J, Marini M, et al.** Proinflammatory effects of TH2 cytokines in a murine model of chronic small intestinal inflammation. *Gastroenterology.* 2005;128:654-666.
- Baron JH, Connell AM, Kanaghinis TG, et al.** Out-patient treatment of ulcerative colitis. Comparison between three doses of oral prednisone. *Br Med J* 1962; 5302:441- 443
- Bazzoli F, Zagari RM, Pozzato P, et al.** Low dose lansoprazole and clarithromycin plus metronidazole vs full dose lansoprazole and clarithromycin plus amoxicillin for eradication of *H. pylori* infection. *Alimentary Pharmacology&Therapeutics* 2002; 16: 153–158.

- Beart RW.** Surgical intervention in chronic ulcerative colitis. Problems in General Surgery 1993; 10:95-108
- Becher B, Durell BG, Noelle RJ.** IL-23 produced by CNS-resident cells controls T cell encephalitogenicity during the effector phase of experimental autoimmune encephalomyelitis. J Clin Invest. 2003;112:1186-1191.
- Becker C, Wirtz S, Blessing M, Pirhonen J, Strand D, Bechthold O, et al.** Constitutive p40 promoter activation and IL-23 production in the terminal ileum mediated by dendritic cells. J Clin Invest. 2003;112:693-706.
- Bell SJ, Chisholm SA, Owen RJ, Borriello SP and Kamm MA.** Evaluation of Helicobacter species in inflammatory bowel diseases. Alimentray pharmacology and therapeutics 2003; 18: 481.
- Berger A.** How does it work? Helicobacter breath tests. Br Med J 2002; 324: 1263.
- Bermejo F, Boixeda D, Gisbert JP, et al.** Rapid urease test utility for Helicobacter pylori infection diagnosis in gastric ulcer disease Hepatogastroenterology 2002; 49: 572–575.
- Bettoni L, Rizzini FL, Tosoni C, Cattaneo R.** Chronic urticaria induced by eradication therapy of *Helicobacter pylori*: a case report. *Helicobacter* 2002;7:269.
- Bevins CL.** The Paneth cell and the innate immune response. Curr Opin Gastroenterol. 2004;20:572-580.
- Binderow SR, Wexner, SD.** Current Surgical Therapy for Mucosal Ulcerative Colitis. Dis Colon Rectum 1994; 37:610-624
- Bodee G, Marchildon P, Peacock J, Brenner H, Rothenbacher D.** Diagnosis of H. pylori infection in children: comparison of a salivary IgG antibody test with the 13C urea breath test. Clin Diag Laboratory Immunol 2002; 9: 493–495.
- Bohr URM, Primus A, Zagoura A, Glasbrenner B, Wex T, Malfertheiner P.** A group-specific PCR assay for the detection of *Helicobacteraceae* in human gut. *Helicobacter* 2002;7:378–383.

- Bonen DK, Cho JH.** The genetics of inflammatory bowel disease. *Gastroenterology*. 2003;124:521-536.
- Bouma G, Strober W.** The immunological and genetic basis of inflammatory bowel disease. *Nat Rev Immunol*. 2003;3:521-533.
- Braat H, Rottiers P, Huyghebaert N, et al.** Interleukin-10 producing lactococcus lactis for the treatment of Crohns disease. *Gastroenterology*. 2005;128(supp2):A-104.
- Bredvik BK, Tocme, SD.** Ocular manifestations of immunological and rheumatological inflammatory disorders. *Current Opinions in Ophthalmology* 1995; 6:92- 96
- Broody TJ, Warren EF, Leis SM, Surace R, Ashman O.** Treatment of ulcerative colitis using fecal bacteriotherapy. *J Clin Gastroenterol* 2003; 37: 42-47.
- Broody TJ, Warren EF, Leis SM, Surace R, Ashman O, Siarakas S.** Bacteriotherapy using fecal flora: toying with human motions. *J Clin Gastroenterol* 2004; 38: 475-483.
- Bulajic M, Maisonneuve P, Schneider Brachert W, et al.** *Helicobacter pylori* and the risk of benign and malignant biliary tract disease. *Cancer* 2002;95:1946–1953.
- Bullens DM, Kasran A, Thielemans K, Bakkus M, Ceuppens JL.** CD40L-induced IL-12 production is further enhanced by the Th2 cytokines IL-4 and IL-13. *Scand J Immunol*. 2001;53:455-463.
- Cahill RJ, CJ Flotz, JG Fox, CA Dangler, F Powrie, and DB Schauer.** Inflammatory bowel disease: an immune mediated condition triggered by bacterial infection with *Helicobacter hepaticus*. *Infect Immun* 1997; 65: 3126-3133.
- Camargo PL, Alfieri AA, Bracarense A, Menoli R, Spinosa SR, Hagiwara MK.** Use of polymerase chain reaction and enzymatic cleavage in the identification of *Helicobacter*

- spp. in gastric mucosa of human beings from North Parana, *Mem Inst Oswaldo Cruz* 2003; 98: 265–268.
- Carlioni E, Cremonini F, Di Caro S, et al.** *Helicobacter pylori*-related extradiigestive diseases and effects of eradication therapy. *Dig Liver Dis* 2000;32: 214–216.
- Caroline DF, Friedman AC.** The radiology of inflammatory bowel disease. *Med Clin North Am* 1994; 78:1353- 1385
- Cavanaugh J.** International collaboration provides convincing linkage replication in complex disease through analysis of a large pooled data set: Crohn disease and chromosome 16. *Am J Hum Genet.* 2001;68:1165-1171.
- Chen TS, Chang FY, Lee SD.** Extending the reading time increases the accuracy of rapid whole blood test for the diagnosis of *H. pylori* infection. *J Gastroenterol Hepatol* 2001; 16: 1341–1350.
- Chen W, Li D, Cannan RJ, Stubbs RS.** Common presence of *Helicobacter* DNA in the gallbladder of patients with gallstone diseases and controls. *Dig Liver Dis* 2003;35:237–243.
- Chiba N, Van Zanten SJ, Sinclair P, Ferguson RA, Escobedo S, Grace E.** Treating *H. pylori* infection in primary care patients with uninvestigated dyspepsia: the Canadian adult positive (CADET-Hp) randomised controlled trial. *Br Med J* 2002; 324: 1012–1016.
- Chisholm SA, Owen RJ.** Development and application of a novel screening PCR assay for direct detection of ‘*Helicobacter heilmannii*’-like organisms in human gastric biopsies in Southeast England. *Diagn Microbiol Infect Dis* 2003; 46: 1–7.
- Choe YH, Kim SK, Hong YC.** The relationship between *Helicobacter pylori* infection and iron deficiency: seroprevalence study in 937 pubescent children. *Arch Dis Child* 2003;88:178.
- Choi IJ, Jung HC, Choi KW, et al.** Efficacy of low dose clarithromycin triple therapy and tinidazole containing triple therapy for *H.*

pylori eradication. *Alimentary Pharmacology&Therapeutics* 2002; 16: 145–151.

Chow WH, Blaser MJ, Blot WJ, et al. An inverse relation between cagA+ strains of *Helicobacter pylori* infection and risk of esophageal and gastric cardia adenocarcinoma. *Cancer Res* 1998; 58: 588-590.

Claesson, MH, A Rudolphi, K Kofoed, SS Poulsen, and J Reimann . CD4+ T lymphocytes injected into severe combined immunodeficient (SCID) mice lead to an inflammatory and lethal bowel disease. *Clin Exp Immunol* 1996; 104: 491-500.

Colin R. Duodenal ulcer healing with 1 week eradication triple therapy followed or not by antisecretory treatment: a multicentre double blind placebo controlled trial. *Alimentary Pharmacology&Therapeutics* 2002; 16: 1157–1162.

Cominelli F. Cytokine-based therapies for Crohn's disease—new paradigms. *N Engl J Med.* 2004;351:2045-2048.

Coppola N, de Stefano G, Marrocco C, et al. Absence of *Helicobacter* spp in the liver of patients with primary or metastatic liver cancer. *Hepatology* 2002;36:1300–1301.

Corrao G, Tragnone A, Caprilli R, et al. Risk of inflammatory bowel disease attributable to smoking, oral contraception and breastfeeding in Italy: a nationwide case-control study. Cooperative Investigators of the Italian Group for the Study of the Colon and the Rectum (GISC). *Int J Epidemiol* 1998;27:397- 404

Correa P. Human gastric carcinogenesis: a multistep and multifactorial process-First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. *Cancer Res* 1992; 52: 6735-6740.

Cuthbert AP, Fisher SA, Mirza MM, King K, Hampe J, Croucher PJ, et al. The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease. *Gastroenterology.* 2002;122:867-874.

- D'Haens G, Lemmens L, Geboes K, et al.** Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. *Gastroenterology* 2001; 120:1323-1329
- Danese S, Sans M, Fiocchi C.** Inflammatory bowel disease: the role of environmental factors. *Autoimmun Rev.* 2004; 3: 394-400.
- Day AS, Sherman PM.** Accuracy of office based immunoassay for the diagnosis of H. pylori infection in children. *Helicobacter* 2002; 7: 205–209.
- De Keyser F, Elewaut D, De Vos M, et al.** Bowel inflammation and the spondyloarthropathies. *Rheum Dis Clin North Am* 1998; 24:785-813
- Desreumaux P, Brandt E, Gambiez L, Emilie D, Geboes K, Klein O, et al.** Distinct cytokine patterns in early and chronic ileal lesions of Crohn's disease. *Gastroenterology.* 1997;113:118-126
- Deveroede G.** Risk of cancer in inflammatory bowel disease. In: Winawer SJ, Schottenfeld, D, Sherlock, P, ed *Colorectal cancer: Prevention, epidemiology, and screening.* New York: Raven Press 1980; 325-334
- Dickinson RJ, Ashton MG, Axon AT, et al.** Controlled trial of intravenous hyperalimentation and total bowel rest as an adjunct to the routine therapy of acute colitis. *Gastroenterology* 1980; 79:1199- 1204
- Di Mario et al.** *Dig Liver Dis* 2003 ;35 (10):706-10.
- Di Mario et al.** *J Clin Gastroenterol* 2003 ;36 (5):396-8.
- Dooley CP, Cohen H, Fitzgibbons PL, et al.** Prevalence of *Helicobacter pylori* infection and histologic gastritis in asymptomatic persons. *N Engl J Med* 1989; 321: 1562-1566.
- Dore MP, Graham DY, Mele R, et al.** Colloidal bismuth subcitrate based twice a day quadruple therapy as primary or salvage therapy for H. pylori infection. *Am J Gastroenterol* 2002; 97: 857–860.

- Drazenovich NL, Franklin CL, Livingston RS, Besselsen DG.** Detection of rodent *Helicobacter* spp. by use of fluorogenic nuclease polymerase chain reaction assays. *Comparative Med* 2002;52:347–353.
- Duerr RH.** Update on the genetics of inflammatory bowel disease. *J Clin Gastroenterol*. 2003;37:358-367.
- Eaden JA, Abrams KR, Mayberry JF.** The risk of colorectal cancer in ulcerative colitis: a meta-analysis. *Gut* 2001; 48:526-535
- Eckmann L, Karin M.** NOD2 and Crohn's disease: loss or gain of function? *Immunity*. 2005;22:661-667.
- Eidelwein AP, Cuffari C, Abadom V, Oliva-Hemker M.** Infliximab efficacy in pediatric ulcerative colitis. *Inflamm Bowel Dis*. 2005; 11: 213-218.
- Ekbom A, Helmick C, Zack M, et al.** Ulcerative colitis and colorectal cancer. A population-based study. *N Engl J Med* 1990; 323:1228-1233
- Elizabeth S, et al.** *Gastroenterol Clin N Am* 35 (2006) 355-365
- Ertem D, Pehlivanoglu E.** *Helicobacter pylori* may influence height in children independent of socioeconomic factors. *J Pediatr Gastroenterol Nutr* 2002;35:232–233.
- Eslick GD, Yan P, Xia HHX, Murray H, Spurrett B, Talley NJ.** Foetal intrauterine growth restrictions with *Helicobacter pylori* infection. *Alimentary Pharmacology&Therapeutics* 2002;16:1677–1682.
- Espinola Klein C, Rupprecht HJ, Blankenberg S, et al.** Impact of infectious burden on progression of carotid atherosclerosis. *Stroke* 2002;33:2581–2586.
- Everhart JE, Kruszon-Moran D, Perez-Perez G.** Reliability of *H. pylori* and *cagA* serological assays. *Clin Diag Laboratory Immunol* 2002; 9: 412–416.
- Fallone CA, Chiba N, Buchan A, Su B, Taylor D.** Two decades of *Helicobacter pylori*: a review of the Fourth Western Pacific

- Helicobacter Congress. *Can J Gastroenterol* 2002;16:559–563.
- Fan X-G, Peng Xi-N, Huang Y, Yakoob J, Wang Z-M, Chen Y-P.** *Helicobacter* species ribosomal DNA recovered from the liver tissue of Chinese patients with primary hepatocellular carcinoma. *Clin Infect Dis* 2002;35:1555–1557.
- Farmer RG, Easley KA, Rankin GB.** Clinical patterns, natural history, and progression of ulcerative colitis. A longterm follow-up of 1116 patients. *Dig Dis Sci* 1993; 38:1137-1146
- Farrel RJ and JT La Mont.** Microbial factors in inflammatory bowel disease. *Gastroenterol Clin N Am* 2002; 31: 41-62.
- Farrokhyar F, Swarbrick ET, Grace RH, et al.** Low mortality in ulcerative colitis and Crohn’s disease in three regional centers in England. *Am J Gastroenterol* 2001; 96:501-507
- Faubion WA, Jr, Loftus EV Jr, Harmsen WS, et al.** The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. *Gastroenterology* 2001; 121:255-260
- Fazio VW.** Toxic megacolon in ulcerative colitis and Crohn’s colitis. *Clin Gastroenterol* 1980; 9:389-407
- Fedorak RN, Gangl A, Elson CO, Rutgeerts P, Schreiber S, Wild G, et al.** Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn’s disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. *Gastroenterology*. 2000; 119: 1473-1482.
- Feng S, Hodzic E, Kendall LV, Smith A, Freet K, Barthold SW.** Cloning and expression of a *Helicobacter bilis* immunoreactive protein. *Clin Diagn Lab Immunol* 2002;9:627–632.
- Fermer C, Lindberg AV, Feinstein RE.** Development and use of a simple polymerase chain reaction assay to screen for *Helicobacter* spp. & *Hhepaticus* in intestinal and fecal samples from laboratory mice. *Comparative Med* 2002;52:518–522.

- Fernandez KR, Hansen LM, Vandamme P, Beaman BL, Solnick JV.** Captive rhesus monkeys (*Macaca mulatta*) are commonly infected with *Helicobacter cinaedi*. *J Clin Microbiol* 2002; 40:1908–1912.
- Figura N, Palazzuoli A, Faglia S, et al.** Infection by CagA-positive *Helicobacter pylori* strains in patients with ischemic heart disease – Prevalence and association with exercise-induced electrocardiographic abnormalities. *Dig Dis Sci* 2002;47:831–836.
- Figura N, Piomboni P, Ponzetto A, et al.** *Helicobacter pylori* infection and infertility. *Eur J Gastroenterol Hepatol* 2002;14:663–669.
- Fiocchi C.** Inflammatory bowel disease: etiology and pathogenesis. *Gastroenterology*. 1998;115:182-205.
- Fischbach LA, et al.** *Aliment Pharmacol Ther* 2004; 20(10):1071-82
- Flotz CJ, JG Fox, RJ Cahill, RC Murphy, L Yan, B Shames and DB Shauer.** Spontaneous inflammatory bowel disease in multiple mutant mouse lines: association with colonization by *Helicobacter hepaticus*. *Helicobacter* 1998; 3: 69-78.
- Forrest EH, MacKenzie JF, Stuart RC, Morris AJ.** H. pylori eradication for peptic ulceration: an observational study in a Scottish primary care setting. *Scott Med J* 2002; 47: 28–33.
- Fort M, Lesley R, Davidson N, Menon S, Brombacher F, Leach M, et al.** IL-4 exacerbates disease in a Th1 cell transfer model of colitis. *J Immunol*. 2001;166:2793-800.
- Fox JG, FE Dewhirst, JG Tully, BJ Paster, L Yan, NS Taylor, MJ Collins, PL Gorelick and JM Ward.** *Helicobacter hepaticus* sp. Nov., an microaerophilic bacterium isolated from livers and intestinal mucosal scrapings from mice. *J Clin Microbiol* 1994; 32: 1238-1245.
- Fox JG, L Handt, S Xu, Z Shen, FE Dewhirst, BJ Paster, CA Dangler, K Lodge, S Motzel and H Klein.** Novel *Helicobacter* species

isolated from rhesus monkeys with chronic idiopathic colitis. *J Med Microbiol* 2001; 50: 421-429.

Fox JG, L Yan, B Shames, J Campbell, JC Murphy and X Li. Persistent hepatitis and enterocolitis in germfree mice infected with *Helicobacter hepaticus*. *Infect Immun* 1996; 64: 3673-3681.

Fox JG, Shen ZL, Xu SL, et al. *Helicobacter marmotae* sp nov isolated from livers of woodchucks and intestines of cats. *J Clin Microbiol* 2002; 40: 2513–2519.

Fox JG, X LI, L Yan, R J Cahill, R Hurley, R Lewis and JC Murphy. Chronic proliferative hepatitis in A/JCr mice associated with persistent *Helicobacter hepaticus* infection: a model of *Helicobacter* induced carcinogenesis. *Infect Immun* 1996; 64: 1548-1558.

Franceschi F, Armuzzi A, Cremonini F, et al. D13 CO₂ excretion and expression of dyspeptic symptoms in patients evaluated for *H. pylori* infection 13C Urea Breath Test. *Dig Dis Sci* 2002; 47: 804–808.

Franceschi F, Sepulveda AR, Gasbarrini A, et al. Cross-reactivity of Anti-CagA antibodies with vascular wall antigens – Possible pathogenic link between *Helicobacter pylori* infection and atherosclerosis. *Circulation* 2002;106:430–434.

Franceschi FM, Genta RM, Sepulveda AR. Gastric mucosa. long term outcome after cure of *H. pylori* infection. *J Gastroenterol*; 2002; 37: 17–23.

Friend DR. Issues in oral administration of locally acting glucocorticoids for treatment of inflammatory bowel disease. *Alimentary Pharmacological Therapy* 1998; 12:591-603

Fukuda K, Kuroki T, Tajima Y, et al. Comparative analysis of *Helicobacter* DNAs and biliary pathology in patients with and without hepatobiliary cancer. *Carcinogenesis* 2002;23:1927–1931.

Furuta T, Shirai N, Xiao F, Takashima M, Hanai H. Effect of *Helicobacter pylori* infection and its eradication on

- nutrition. *Alimentary Pharmacology&Therapeutics* 2002;16:799–806.
- Fuss IJ, Boirivant M, Lacy B, Strober W.** The interrelated roles of TGF-beta and IL-10 in the regulation of experimental colitis. *J Immunol.* 2002;168:900-908.
- Fuss IJ, Neurath M, Boirivant M, Klein JS, de la Motte C, Strong SA, et al.** Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. *J Immunol.* 1996;157:1261-1270.
- Gabrielli M, Pola P, Gasbarrini A.** *Helicobacter pylori*, CagA-positive strains, and ischemic stroke. *Stroke* 2002;33:1453.
- Garcia A, Erdman SE, Xu S, et al.** Hepatobiliary inflammation, neoplasia, and argyrophilic bacteria in a ferret colony. *Vet Pathol* 2002;39:173–179.
- Garside P.** Cytokines in experimental colitis [Editorial]. *Clin Exp Immunol.* 1999;118:337-339.
- Gasbarrini A, Franceschi F, Armuzzi A, et al.** Extradigestive manifestations of *Helicobacter pylori* gastric infection. *Gut* 1999;45:I9–I12.
- Georgopoulos SD, Ladas SD, Karatapanis S, et al.** Effectiveness of two quadruple tetracycline or clarithromycin containing second line *H. pylori* eradication therapies. *Alimentary Pharmacology&Therapeutics* 2002; 16: 569–575.
- Gilger MA, Tolia V, Johnson A, et al.** The use of an oral fluid immunoglobulin G ELISA for the detection of *H. pylori* infection in children. *Helicobacter* 2002; 7: 105–110.
- Gisbert JP, Cabrera MD, Mdel M, Pajares JM.** Stool antigen test for initial *H. pylori* diagnosis and for confirmation of eradication after therapy. *Med Clin (Barc)* 2002; 118: 401–404.

- Goldman CG, Loureiro JD, Quse V, et al.** Evidence of *Helicobacter* sp in dental plaque of captive dolphins (*Tursiops gephyreus*). *J Wildlife Dis* 2002;38:644–648.
- Goodwin CS, Armstrong JA, Chilvers T, et al.** Transfer of *Campylobacter pylori* and *Campylobacter mustelae* to *Helicobacter* gen. nov. as *Helicobacter pylori* comb. nov. & *Helicobacter mustelae* comb. nov., respectively. *Int J Syst Bacteriol* 1989; 39: 397-405.
- Gor DO, Rose NR, Greenspan NS.** TH1-TH2: a procrustean paradigm. *Nat Immunol.* 2003;4:503-505.
- Gotoh A, et al.** *Helicobacter* 2002;7(3): 183-91
- Graham et al.** *Aliment Pharmacol Ther* 2004; 14 (2): 211-5
- Grant CS, Dozois RR.** Toxic megacolon: ultimate fate of patients after successful medical management. *Am J Surg* 1984; 147:106-110
- Greenstein AJ, Sachar DB, Gibas A, et al.** Outcome of toxic dilatation in ulcerative and Crohn's colitis. *J Clin Gastroenterol* 1985; 7:137-143
- Grehan M, Tamotia G, Robertson B, Mitchell H.** Detection of *Helicobacter* colonization of the murine lower bowel by genus-specific PCRdenaturing gradient gel electrophoresis. *Appl Environ Microbiol* 2002;68:5164–5166.
- Gurbuz AK, et al.** *South Med J* 2005; 98(11):1095-7
- Guttner Y et al.** *Aliment Pharmacol Ther* 2003;17(1):125-9
- Haghighi DB, Lashner BA.** Left-sided ulcerative colitis. *Gastroenterol Clin North Am* 2004; 33:271-284
- Haider AW, Wilson PWF, Larson MG, et al.** The association of seropositivity to *Helicobacter pylori*, *Chlamydia pneumoniae*, and cytomegalovirus with risk of

- cardiovascular disease: a prospective study. *J Am Coll Cardiol* 2002;40:1408–1413.
- Hampe J, Cuthbert A, Croucher PJ, Mirza MM, Mascheretti S, Fisher S, et al.** Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. *Lancet*. 2001;357:1925-1928.
- Hamilton Miller.** Clinical trials with probiotics in H. pylori colonized subjects. *Alimentary Pharmacological therapy*. 2006; 32(8): 1077-1086.
- Hanauer SB.** Inflammatory bowel disease. *N Engl J Med* 1996; 334: 841-848.
- Hanninen ML, Utriainen M, Happonen I, Dewhirst FE.** *Helicobacter* sp flexispira 16S rDNA taxa 1, 4 and 5 and Finnish porcine *Helicobacter* isolates are members of the species *Helicobacter trogontum* (taxon 6). *Int J System Evol Microbiol* 2003; 53: 425–433.
- Harper CMG, Xu S, Feng Y, et al.** Identification of novel *Helicobacter* spp. from a Beluga whale. *Appl Environ Microbiol* 2002;68:2040–2043.
- Harris KA, Fidler KJ, Hartley JC, et al.** Unique case of *Helicobacter* sp osteomyelitis in an immunocompetent child diagnosed by broad-range 16S PCR. *J Clin Microbiol* 2002;40:3100–3103.
- Hashino S, Mori A, Suzuki S, et al.** Platelet recovery in patients with idiopathic thrombocytopenic purpura after eradication of *Helicobacter pylori*. *Int J Hematol* 2003;77:188–191.
- Hawley PR.** Emergency surgery for ulcerative colitis. *World J Surg* 1988; 12:169- 173
- Hegedus O, Ryden J, Rehnberg AS, Nilsson S, Hellstrom PM.** Validated accuracy of a novel urea breath test for rapid H. pylori detection and in-office analysis. *Eur J Gastroenterol Hepatol* 2002; 14: 513–520.

- Hermiston ML, Gordon JJ.** Inflammatory bowel disease and adenomas in mice expressing a dominant negative N-cadherin. *Science*. 1995;270:1203-1207.
- Hien Quoc Huynh, Richard T. L. Couper, Cuong D. Tran, et al.** N-Acetylcysteine, a novel treatment for H.pylori infection. Springer Netherlands 2004;49:11-12.
- Hino M, Yamane T, Park K, et al.** Platelet recovery after eradication of *Helicobacter pylori* in patients with idiopathic thrombocytopenic purpura. *Ann Hematol* 2003;82:30–32.
- Hommes D, Beart F, Van Assche C, et al.** Management of recent onset Crohn's disease- A controlled randomised trial comparing step-up and top-down therapy. 2005.
- Horne BD, Muhlestein JB, Strobel GG, Carlquist JF, Bair TL, Anderson JL.** Greater pathogen burden but not elevated C-reactive protein increases the risk of clinical restenosis after percutaneous coronary intervention. *Am Heart J* 2002; 144: 491–500.
- Hoshi K, Yamano Y, Mitsunaga A, Shimizu S, Kagawa J, Ogiuchi H.** Gastrointestinal diseases and halitosis: association of gastric *Helicobacter pylori* infection. *Int Dental J* 2002;52:207–211.
- Hugot JP, Chamaillard M, Zouali H, Lesage S, Cézard JP, Belaiche J, et al.** Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. *Nature*. 2001;411:599-603.
- Hugot JP, Laurent-Puig P, Gower-Rousseau C, Olson JM, Lee JC, Beaugier L, et al.** Mapping of a susceptibility locus for Crohn's disease on chromosome 16. *Nature*. 1996;379:821-823.
- Hung CT, Leung WK, Chan FK, Sung JJ.** Comparison of two new rapid serology tests for the diagnosis of H. pylori infection in Chinese patients. *Dig Liver Dis* 2002; 34: 111–115.

- Hwang CY, Han HR, Youn HY.** Prevalence and clinical characterization of gastric *Helicobacter* species infection of dogs and cats in Korea. *J Vet Sci* 2002; 3: 123–133.
- Hynes SO, McGuire J, Falt T, Wadstrom T.** The rapid detection of low molecular mass proteins differentially expressed under biological stress for four *Helicobacter* spp. using ProteinChip (R) technology. *Proteomics* 2003; 3: 273–278.
- Hynes SO, McGuire J, Wadstrom T.** Potential for proteomic profiling of *Helicobacter pylori* and other *Helicobacter* spp. using a ProteinChip (R) array. *FEMS Immunol Med Microbiol* 2003;36:151–158.
- Hynes SO, Teneberg S, Roche N, Wadstrom T.** Glycoconjugate binding of gastric and enterohepatic *Helicobacter* spp. *Infect Immun* 2003;71:2976–2980.
- Inaba T, Mizuno M, Kawai K, et al.** Randomised open trial for comparison of PPI in triple therapy for H. pylori infection in relation to CYP2C19 genotype. *J Gastroenterol Hepatol* 2002; 17: 748–753.
- Isacov V, Domareva I, Koudryavtseva L, Maev I, Ganskaya Z.** Furazolidone based triple rescue therapy vs quadruple rescue therapy for the eradication of H. pylori resistant to metronidazole. *Alimentary Pharmacology&Therapeutics* 2002; 16: 1277– 1282.
- Kaklikkaya N, Ozgur O, Aydin F, Cobanoglu U.** *Helicobacter heilmannii* as causative agent of chronic active gastritis. *Scand J Infect Dis* 2002; 34:768–770.
- Kamiya S, Yamaguchi H, Osaki T, Toyoda A, Taguchi H.** Microbiological evaluation of H. pylori stool antigen detection (HpSA) kit; its specificity and reactivity with coccoid form of H. Pylori 2002; 76: 378–384.
- Kane SV, Bjorkman DJ.** The efficacy of oral 5-ASAs in the treatment of active ulcerative colitis: a systematic review. *Rev Gastroenterol Disord* 2003; 3: 210-218
- Kawakami E, Machado RS, Reber M, Patricio FR.** 13C urea breath test with infrared spectroscopy for diagnosing H. pylori

infection in children and adolescents. *J Paediat Gastroenterol Nutr* 2002; 35: 39–43.

Kazerooni T, Taallom M, Ghaderi AA. *Helicobacter pylori* seropositivity in patients with hyperemesis gravidarum. *Int J Gynecol Obstet* 2002;79:217–220.

Kilmartin CM. Dental implications of *Helicobacter pylori*. *J Can Dent Assoc* 2002;68:489–493.

Kim PS, Lee JW, Pai SH, et al. Detection of H. Pylori Antigen Stool Enzyme Immunoassay. *Yonsei Med J* 2002; 43: 7–13.

Kirk AP, Lennard-Jones JE. Controlled trial of azathioprine in chronic ulcerative colitis. *Br Med J (Clin Res Ed)* 1982; 284:1291-1292

Kita T, Sakaeda T, Aoyama N, et al. Optimal dose of omeprazole for CYP2C19 extensive metabolizers in anti-H. pylori therapy: pharmacokinetic considerations. *Biol Pharm Bull* 2002; 25: 923–927.

Kobayashi D, Eishi Y, Ohkusa T, et al. Gastric mucosal density of H. pylori estimated by real-time PCR compared with results of urea breath test and histological grading. *J Med Micro* 2002; 51: 305–311.

Kogo T, Inoue H, Ishii C, Okazaki Y, Domon H, Utui Y. Effect of Plaunotol in combination with clarithromycin or amoxicillin on H. pylori in vitro and in vivo. *J Antimicrob Chemother* 2002; 50: 133–136.

Kohda K, Kuga T, Kogawa K, et al. Effect of *Helicobacter pylori* eradication on platelet recovery in Japanese patients with chronic idiopathic thrombocytopenic purpura and secondary autoimmune thrombocytopenic purpura. *Br J Haematol* 2002;118:584–588.

Kohn A, Prantera C, Pera A, Cosentino R, Sostegni R, Daperno M. Infliximab in the treatment of severe ulcerative colitis: a follow up study. *Eur Rev Med Pharmacol Sci.* 2004;8:235-237.

- Kolho KL, Korhonen J, Verkasalo M, Lindahl H, Savilahti E, Rautelin H.** H. pylori serology at diagnosis and follow-up of biopsy verified infection in children. *Scand J Infec Dis* 2002; 34: 177–182.
- Konturek PC, Bielanski W, Konturek SJ, et al.** Progastrin and cyclooxygenase-2 in colorectal cancer. *Dig Dis Sci* 2002;47:1984–1991.
- Kornilovs'ka I, Nilsson I, Utt M, Ljungh A, Wadstrom T.** Immunogenic proteins of *Helicobacter pullorum*, *Helicobacter bilis* and *Helicobacter hepaticus* identified by two-dimensional gel electrophoresis and immunoblotting. *Proteomics* 2002;2:775–783.
- Kornbluth A, Sachar DB.** Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. *Am J Gastroenterol* 2004; 99: 1371-1385.
- Kosiewicz MM, Nast CC, Krishnan A, Rivera-Nieves J, Moskaluk CA, Matsumoto S, et al.** Th1-type responses mediate spontaneous ileitis in a novel murine model of Crohn's disease. *J Clin Invest.* 2001;107:695-702.
- Kostaki M, Fessatou S, Karpathios T.** Refractory iron-deficiency anaemia due to silent *Helicobacter pylori* gastritis in children. *Eur J Pediatr* 2003; 162: 177–179.
- Kostia S, Veijalainen P, Hirvi U, Hanninen M-L.** Cytolethal distending toxin B gene (*cdtB*) homologues in taxa 2, 3 and 8 and in six canine isolates of *Helicobacter* sp. flexispira. *J Med Microbiol* 2003;52:103–108.
- Kowalski M, Rees W, Konturek PC, et al.** Detection of *Helicobacter pylori* specific DNA in human atheromatous coronary arteries and its association to prior myocardial infarction and unstable angina. *Dig Liver Dis* 2002;34:398–402.
- Kubota K, Shimoyama S, Shimizu N, et al.** Studies of ¹³C urea breath test for diagnosis of H. pylori infection in patients after partial gastrectomy. *Digestion* 2002; 65: 82–86.

- Kugathasan S, Werlin SL, Martinez A, Rivera MT, Heikenen JB, Binion DG.** Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease. *Am J Gastroenterol.* 2000;95:3189.
- Kühn R, J Löhler, D Rennick, K Rajewsky and W Muller.** Interleukin 10 deficient mice develop chronic enterocolitis. *Cell* 1993; 75: 263-274.
- Kullberg MC, JM Ward, PL Gorelick, P Caspar, S Hieny, A Cheever, D Jankovic and A Sher.** *Helicobacter hepaticus* triggers colitis in specific pathogen free interleukin-10 (IL-10) deficient mice through and IL-12 and gamma interferon dependent mechanism. *Infect Immun* 1998; 66: 5157-5166.
- Kwon JH, Keates S, Bassani L, Mayer LF, Keates AC.** Colonic epithelial cells are a major site of macrophage inflammatory protein 3alpha (MIP-3alpha) production in normal colon and inflammatory bowel disease. *Gut.* 2002;51:818-826.
- Ladas SD, Varzakakos I, Malamou H, et al.** Evaluation on a single step serological assay for laboratory diagnosis of *H. pylori* infection. *Eur J Clin Microbiol Infec Dis* 2002; 21: 56–59.
- Lee CL, Liu CC, Liao CC, Tu TC, Chen TK, Wu CH.** Reuse of CLO test in the diagnosis of *Helicobacter pylori* infection. *J Formos Med Assoc* 2002; 101: 298–300.
- Lennard-Jones JE, Melville DM, Morson BC, et al.** Precancer and cancer in extensive ulcerative colitis: findings among 401 patients over 22 years. *Gut* 1990; 31:800-806
- Limburg PJ, Stolzenberg Solomon RZ, Colbert LH, et al.** *Helicobacter pylori* seropositivity and colorectal cancer risk: a prospective study of male smokers. *Cancer Epidemiol Biomarkers Prev* 2002;11:1095–1099.
- Lin CK, Hsu PI, Lai KH, et al.** One week quadruple therapy is an effective salvage regimen for *H. pylori* infection in patients after failure of standard triple therapy. *J Clin Gastroenterol* 2002; 34: 547–551.

- Linskens RK, Huijsdens XW, Savelkoul PH, Vandenbroucke-Grauls CM, Meuwissen SG.** The bacterial flora in inflammatory bowel disease: current insights in pathogenesis and the influence of antibiotics and probiotics. *Scand J Gastroenterol Suppl.* 2001:29-40.
- Lodes MJ, Cong Y, Elson CO, Mohamath R, Landers CJ, Targan SR, et al.** Bacterial flagellin is a dominant antigen in Crohn disease. *J Clin Invest.* 2004;113:1296-1306.
- Lofberg R, Brostrom O, Karlen P, et al.** Colonoscopic surveillance in longstanding total ulcerative colitis--a 15- year follow-up study. *Gastroenterology* 99:1021-1031, 1990
- Loffeld RJ, Werdmuller BF, Kuster JG, et al.** Colonization with cagA-positive *Helicobacter pylori* strains inversely associated with reflux esophagitis and Barrett's esophagus. *Digestion* 2000; 62: 95-99.
- Loftus EV, Kane, DB.** Systematic review: short-term adverse effects of 5- aminosalicylic acid agents in the treatment of ulcerative colitis. *Alimentary Pharmacological Therapy* 19:179-189, 2004
- M ow WS, Landers CJ, Steinhart AH, Feagan BG, Croitoru K, Seidman E, et al.** High-level serum antibodies to bacterial antigens are associated with antibiotic-induced clinical remission in Crohn's disease: a pilot study. *Dig Dis Sci.* 2004;49:1280-1286.
- Mahadeva S, Connelly J, Sahay P.** A test and treat policy does not save endoscopy workload in a non-referral hospital. *Eur J Gastroenterol Hepatol* 2002; 14: 257–262.
- Majka J, Rog T, Konturek PC et al.** Influence of chronic *Helicobacter pylori* infection on ischemic cerebral stroke risk factors. *Med Sci Monit* 2002;8: CR675–84.
- Malfertheiner P, Megraud F, O'Morain C, et al.** Current concepts in the management of *H. pylori* infection – The Maastricht 2–220 Consensus Report. *Alimentary Pharmacology&Therapeutics* 2002; 16: 167–80.

- Malik AA, Ganti AK, Potti A, Levitt R, Hanley JF.** Role of *Helicobacter pylori* infection in the incidence and clinical course of monoclonal gammopathy of undetermined significance. *Am J Gastroenterol* 2002;97:1371–1374.
- Mardh E, Mardh S, Mardh B, Borch K.** Diagnosis of gastritis by means of a combination of serological analysis. *Clin Chim Acta* 2002; 320: 17–27.
- Markowitz J, Grancher K, Kohn N, Lesser M, Daum F.** A multi-center trials of 6-Mercaptopurine and prednisolone in children with newly diagnosed Crohns disease. *Gastroenterology*. 2000; 119: 895-902.
- Marshall BJ, Warren JR.** Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. *Lancet* 1984; 1: 1311-1315.
- Martin .H et al.** *Gastroenterol Clin N Am* 34 (2005) 517-570
- Mason J, Axon AT, Forman D, et al.** The cost effectiveness of population H. pylori screening and treatment: a Markov model using economic data from a randomised control trial. *Alimentary Pharmacology&Therapeutics* 2002; 16:559–968.
- Matsukura N, Yokomuro S, Yamada S, et al.** Association between *Helicobacter bilis* in bile and biliary tract malignancies: *H-bilis* in bile from Japanese and Thai patients with benign and malignant diseases in the biliary tract. *Jpn J Cancer Res* 2002;93:842–847.
- McColl KE, Murray LS, Gillen D, et al.** Randomised trial of endoscopy with testing for *Helicobacter pylori* compared with non-invasive H. pylori testing alone in the management of dyspepsia. *Br Med J* 2002; 324: 999–1002.
- McLeod RS, Churchill DN, Lock AM, et al.** Quality of life of patients with ulcerative colitis preoperatively and postoperatively. *Gastroenterology* 101: 1307-1313, 1991
- Mehta DS, Wurster AL, Grusby MJ.** Biology of IL-21 and the IL-21 receptor. *Immunol Rev.* 2004;202:84-95.

- Mendeloff AI, Calkins, BM.** The epidemiology of idiopathic inflammatory bowel disease. Philadelphia.1995;31
- Mennechet FJ, Kasper LH, Rachinel N, Li W, Vandewalle A, Buzoni-Gatel D.** Lamina propria CD4+ T lymphocytes synergize with murine intestinal epithelial cells to enhance proinflammatory response against an intracellular pathogen. *J Immunol.* 2002;168:2988-2996.
- Michel M, Khellaf M, Desforges L, et al.** Autoimmune thrombocytopenic purpura and *Helicobacter pylori* infection. *Arch Int Med* 2002;162:1033–1036.
- Mikkola KA, Jarvinen HJ.** Management of fulminating ulcerative colitis. *Ann Chir Gynaecol* 1992; 81:37-41
- Mir-Madjlessi SH, Farmer RG, Easley KA, et al.** Colorectal and extracolonic malignancy in ulcerative colitis. *Cancer* 1986; 58:1569-1574
- Misawa N, Kawashima K, Kondo F, Kushima E. Kushima Ki, Vandamme P.** Isolation and characterization of *Campylobacter*, *Helicobacter*, and *Anaerobiospirillum* strains from a puppy with bloody diarrhea. *Vet Microbiol* 2002;87:353–364.
- Mombaerts, P, E Mizoguchi, MJ Grusby, LH Glimcher, AK Bhan, and S Tonegawa.** Spontaneous development of inflammatory bowel disease in T cell receptor mutant mice. *Cell* 1993; 75: 275-282.
- Monsen U, Sorstad J, Hellers G, et al.** Extracolonic diagnoses in ulcerative colitis: an epidemiological study. *Am J Gastroenterol* 1990; 85:711-716
- Morales A, Hurtado C, Madrid AM, Pimentel C, Espinosa MN.** An Elisa stool test to detect *H. pylori* infection. *Rev Med Chil* 2002; 130: 61–65.
- Mow WS, Vasiliasukas EA, Lin YC, Fleshner PR, Papadakis KA, Taylor KD, et al.** Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. *Gastroenterology.* 2004;126:414-424.

- Mowschenson PM, Critchlow JF, Rosenberg SJ, et al.** Factors favoring continence, the avoidance of a diverting ileostomy and small intestinal conservation in the ileoanal pouch operation. *Surg Gynecol Obstet* 1993; 177:17- 26
- Nakayama Y et al.** *Expert Rev Anti Infect Ther* 2004; 2(4):599-610
- Nivatvongs S.** Ulcerative colitis. In: Gordon PH, Nivatvongs, S, ed *Principles and practice of surgery for the colon, rectum, and anus.* St Louis: Quality Medical publishing 1992; 667-717.
- Nomura A, Stemmermann GN, Chyou PH, et al.** Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. *N Engl J Med* 1991; 325: 1132-1136.
- Nugent FW, Schoetz, DJ.** Chronic ulcerative colitis: Indication for proctectomy. In: Kodner IJ, Fry, RD, Roe, JP, ed *Colon, rectal, and anal surgery.* St. Louis: CV Mosby 1985; 287-296
- O'Shea JJ, Ma A, Lipsky P.** Cytokines and autoimmunity. *Nat Rev Immunol.* 2002; 2: 37-45. Ovid: Bamias: *Ann Intern Med,* Volume 143(12). December 20, 2005: 895-904
- Oakley JR.** Acute ulcerative colitis and toxic dilatation. In: Fazio VW, ed. *Current therapy in colon and rectal surgery.* Philadelphia: BC Decker 1990; 174- 180
- Odaka T, Yamaguchi T, Koyama H, Saisho H, Nomura F.** Evaluation of the H. pylori stool antigen test for monitoring eradication therapy. *Am J Gastroenterol* 2002; 97: 594–599.
- Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, et al.** A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. *Nature.* 2001;411:603-606.
- Oleastro M, Matos R, Cabral J, et al.** Evaluation of a Western blot test, Helico Blot 2.1 in the diagnosis of H. pylori infection in a paediatric population. *Helicobacter* 2002; 7: 210–215.
- Oppmann B, Lesley R, Blom B, Timans JC, Xu Y, Hunte B, et al.** Novel p19 protein engages IL-12p40 to form a cytokine, IL-23,

with biological activities similar as well as distinct from IL-12. *Immunity*. 2000;13:715-725.

Orchard TR, Wordsworth, BP, Jewell, DP. Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. *Gut* 1998; 42:387-391

Palli D, Menegatti M, Masala G, et al. *Helicobacter pylori* infection, anti-cagA antibodies and peptic ulcer: a case control study in Italy *Alimentary Pharmacology & Therapeutics* 2002; 16: 1015–1020.

Palmas F, Pellicano R, Massimetti E, Berrutti M, Fagone S, Rizzetto M. Eradication of *H. pylori* infection with proton pump inhibitor based triple therapy: a randomised study. *Panminerva Med* 2002; 44: 145–147.

Panwala CM, Jones JC, Viney JL. A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, *mdr1a*, spontaneously develop colitis. *J Immunol*. 1998;161:5733-5744.

Parsonnet J, Friedman GD, Vandersteen DP, et al. *Helicobacter pylori* infection and the risk of gastric carcinoma. *N Engl J Med* 1991; 325: 1127-1131.

Parsonnet J, Hansen S, Rodriguez L, et al. *Helicobacter pylori* infection and gastric lymphoma. *N Engl J Med* 1994; 330: 1267-1271.

Passaro DJ, Taylor DN, Gilman RH, Cabrera L, Parsonnet J. Growth slowing after acute *Helicobacter pylori* infection is age-dependent. *J Pediatr Gastroenterol Nutr* 2002;35:522–526.

Patterson MM, Pw OT, Forester NT, et al. Failure of surface ring mutant strains of *Helicobacter mustelae* to persistently infect the ferret stomach. *Infect Immun* 2003;71:2350–5. acid secretion in cat. *Am J Physiol Gastrointest Liver Physiol* 2002; 282: 727–734.

Pearson C, May, G.R., Fick G., et al. Azathioprine for maintaining remission in Crohn's disease. The Cochrane Library. Oxford: Cochrane Collaboration, 1999

- Pedotti R, De Voss JJ, Steinman L, Galli SJ.** Involvement of both “allergic” and “autoimmune” mechanisms in EAE, MS and other autoimmune diseases. *Trends Immunol.* 2003;24:479-484.
- Peek RM Jr, Vaezi MF, Falk GW, et al.** Role of *Helicobacter pylori* cagA (+) strains and specific host immune responses on the development of premalignant and malignant lesions in the gastric cardia. *Int J Cancer* 1999; 82: 520-524.
- Pelletier M, Bouchard A, Girard D.** In vivo and in vitro roles of IL-21 in inflammation. *J Immunol.* 2004; 173: 7521-7530.
- Penna C, Daude F, Parc R, et al.** Previous subtotal colectomy with ileostomy and sigmoidostomy improves the morbidity and early functional results after ileal pouch-anal anastomosis in Società Italiana di Chirurgia ColoRettale ulcerative colitis. *Dis Colon Rectum* 1993; 36:343-348
- Pereira LP, Waisberg J, Andre EA, Zanoto A, Mendes Jr. JP, Soares HP.** Detection of *Helicobacter pylori* in gastric cancer. *Arq Gastroenterol* 2001; 38: 240–246.
- Peterson WL.** *Helicobacter pylori* and peptic ulcer disease. *N Engl J Med* 1991; 324: 1043-1048.
- Pflanz S, Timans JC, Cheung J, Rosales R, Kanzler H, Gilbert J, et al.** IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4(+) T cells. *Immunity.* 2002;16:779-790.
- Pietroiusti A, Diomedi M, Silvestrini M, et al.** Cytotoxin-associated gene-A-positive *Helicobacter pylori* strains are associated with atherosclerotic stroke. *Circulation* 2002;106:580–584.
- Pinna-Pintor M, Arese P, Bona R, et al.** Severe steroid-unresponsive ulcerative colitis: outcomes of restorative proctocolectomy in patients undergoing cyclosporin treatment. *Dis Colon Rectum* 2000; 43:609-613
- Pizarro TT, Arseneau KO, Bamias G, Cominelli F.** Mouse models for the study of Crohn’s disease. *Trends Mol Med.* 2003;9:218-222.

- Podolsky D.** Inflammatory bowel disease. *N Engl J Med* 1991; 325: 928-937.
- Podolsky D.** Inflammatory bowel disease. *N Engl J Med.* 2002;347:417-429.
- Powrie F, M Leach, S Mauze, L Barcomb Caddle, and RL Coffman.** Phenotypically distinct subsets of CD4⁺ T cells or protect from chronic intestinal inflammation in CB17 scid mice. *Int Immunol* 1993; 5: 1461-1471.
- Prasad A, Zhu JH, Halcox JPJ, Wacławski MA, Epstein SE, Quyyumi AA.** Predisposition to atherosclerosis by infections role of endothelial dysfunction. *Circulation* 2002;106:184–190.
- Prehn JL, Mehdizadeh S, Landers CJ, Luo X, Cha SC, Wei P, et al.** Potential role for TL1A, the new TNF-family member and potent costimulator of IFN-gamma, in mucosal inflammation. *Clin Immunol.* 2004;112:66-77.
- Present DH, Korelitz BI, Wisch N, et al.** Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. *N Engl J Med* 1980; 302:981-987
- Qasim A, O'Morain CA.** Review article: Treatment of H. pylori infection and factors influencing eradication. *Alimentary Pharmacology&Therapeutics* 2002; 16(Suppl. 1): 24–30.
- Rachel JC, Charmaine JF, James GF, Charles AD, Fiona P and David BS.** Inflammatory Bowel Disease: an Immunity Mediated condition triggered by bacterial infection with *Helicobacter hepaticus*. *Infection and Immunity* 1997; 65: 8, 3128-3131.
- Rajkumar SV, Kyle RA, Plevak MF, Murray JA, Therneau TM.** *Helicobacter pylori* infection and monoclonal gammopathy of undetermined significance. *Br J Haematol* 2002; 119: 706–708.
- Reuter BK, Pizarro TT.** Commentary: the role of the IL-18 system and other members of the IL-1R/TLR superfamily in innate mucosal immunity and the pathogenesis of inflammatory

- bowel disease: friend or foe? *Eur J Immunol.* 2004;34:2347-2355.
- Rivera-Nieves J, Bamias G, Vidrich A, Marini M, Pizarro TT, McDuffie MJ, et al.** Emergence of perianal fistulizing disease in the SAMP1/YitFc mouse, a spontaneous model of chronic ileitis. *Gastroenterology.* 2003;124:972-982.
- Rivera-Nieves J, Olson T, Bamias G, Bruce A, Solga M, Knight RF, et al.** L-selectin, alpha 4 beta 1, and alpha 4 beta 7 integrins participate in CD4+ T cell recruitment to chronically inflamed small intestine. *J Immunol.* 2005;174:2343-2352.
- Robert JH, Sachar DB, Aufses AH, Jr, et al.** Management of severe hemorrhage in ulcerative colitis. *Am J Surg* 1990; 159:550-555.
- Roggero P, Bonfiglio A, Luzzani S, et al.** H. pylori stool antigen test: a method to confirm eradication in children. *J Paediat* 2002; 140: 775–777.
- Roosendaal R, Kuipers EJ, Vandenbroucke Grauls C, Kusters JG.** *Helicobacter* species are not detectable by 16S rDNA PCR in bile from Dutch patients with common bile duct stones. *Digestion* 2002;66:89–91.
- Rutgeerts P, M Hiele, K Goboos, M Peeters, F Penninck, R Aerts and R Kerremans.** Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. *Gastroenterology* 1995; 108: 1617-1621.
- Sadlack B, H Merz, H Schorke, A Schimpi, A C Feller, and I Horak.** Ulcerative colitis like disease in mice with a disrupted interleukin-2 gene. *Cell* 1993; 75: 253-261.
- Salimi-Khayati A, Sharami H, Mansour-Ghanaei F, Sadri S, Fallah MS.** *Helicobacter pylori* seropositivity and the incidence of hyperemesis gravidarum. *Med Sci Monit* 2003;9: 12–15.
- Sandborn WJ.** Cyclosporine in ulcerative colitis: state of the art. *Acta Gastroenterol Belg* 2001; 64:201-204

- Sandborn WJ, Rachmilewitz R, Hanauer SB, et al.** Infliximab induction and maintenance therapy for ulcerative colitis. *Gastroenterology* 2005;128(supp 2):A-104.
- Sartor RB.** Cytokine regulation of experimental intestinal inflammation in genetically engineered and T-lymphocyte reconstituted rodents. *Aliment. Pharmacol. Ther.* 1996; 10: 36-42.
- Sartor RB.** Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. *Gastroenterology*. 2004;126:1620-1633.
- Satsangi J, Landers CJ, Welsh KI, et al.** The presence of anti-neutrophil antibodies reflects clinical and genetic heterogeneity within inflammatory bowel disease. *Inflamm Bowel Dis* 1998; 4:18-26
- Saunders KE, Z Shen FE Dewhirst, BJ Paster CA Dangler, and JG Fox.** Novel intestinal *Helicobacter* species isolated from cotton top tamarins (*Saguinus oedipus*) with chronic colitis. *J Clin Microbiol* 1999; 37: 146-151.
- Schreiber S, Fedorak RN, Nielsen OH, Wild G, Williams CN, Nikolaus S, et al.** Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. *Gastroenterology*. 2000;119:1461-1472.
- Seldenrijk CA, Morson BC, Meuwissen SG, et al.** Histopathological evaluation of colonic mucosal biopsy specimens in chronic inflammatory bowel disease: diagnostic implications. *Gut* 1991; 32: 1514-1520
- Seo JK, Ko JS, Choi KD.** Serum ferritin and *Helicobacter pylori* infection in children: a seroepidemiologic study in Korea. *J Gastroenterol Hepatol* 2002;17:754–757.
- Serin E, Gumurdulu Y, Kayaselcuk F, Ozer B, Yilmaz U, Boyacioglu S.** Halitosis in patients with *Helicobacter pylori*-positive non-ulcer dyspepsia: an indication for eradication therapy? *Eur J Intern Med* 2003;14:45–48.

- Shames B, JG Fox F Dewhirst, L Yan, Z Shen and NS Taylor.** Identification of widespread *Helicobacter hepaticus* infection in feces in commercial mouse colonies by culture and PCR assay. *J Clin Microbiol* 1995; 33: 2968-2972.
- Sheu BS, Chi CH, Huang CC, Kao AW, Wang YL, Yang HB.** Impact of intravenous omeprazole on *H. pylori* eradication by triple therapy in patients with peptic ulcer bleeding. *Alimentary Pharmacology&Therapeutics* 2002; 16: 137–143.
- Shinozaki JK, Sellon RK, Cantor GH, Besser TE, Mealey KL, Vaden SL.** Fecal polymerase chain reaction with 16S ribosomal RNA primers can detect the presence of gastrointestinal *Helicobacter* in dogs. *J Vet Int Med* 2002;16:426–432.
- Shorner NH, CA Dangler, MD Schrenzel and JG Fox.** *Helicobacter bilis* induced inflammatory bowel disease in scid mice with defined flora. *Infect Immun* 1997; 65: 4858-4864.
- Singh RK, McMahon AD, Patel H, Packard CJ, Rathbone BJ, Samani NJ.** Prospective analysis of the association of infection with CagA bearing strains of *Helicobacter pylori* and coronary heart disease. *Heart* 2002;88:43–46.
- Smieja M, Gnarpe J, Lonn E, et al.** Multiple infections and subsequent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) study. *Circulation* 2003;107:251–257.
- Sokueu S, Suoglu OD, Turkkan E, Elkabes B, Ozden T, Saner G.** *H. pylori* infection in Turkish children with gastrointestinal symptoms and evaluation of serology. *Turk. J Paediat* 2002; 44: 102–108.
- Solnick JV.** Clinical significance of *Helicobacter* species other than *Helicobacter pylori*. *Clin Infect Dis* 2003;36:349–354.
- Stadnyk AW.** Intestinal epithelial cells as a source of inflammatory cytokines and chemokines. *Can J Gastroenterol.* 2002;16:241-246.
- Stone AFM, Mendall MA, Kaski JC, et al.** Effect of treatment for *Chlamydia pneumoniae* and *Helicobacter pylori* on markers of inflammation and cardiac events in patients with acute

coronary syndromes – South Thames trial of antibiotics in myocardial infarction and unstable angina (STAMINA). *Circulation* 2002;106:1219–1223.

Streuker CJ; Bernstein CN; Chan VL; Riddell RH and Croitoru. Detection of species – specific. *Helicobacter* ribosomal DNAs in intestinal biopsy samples from a population based cohort of patients with ulcerative colitis. *J Clinical Microbiology*; 2004; 42(2): 660-664.

Strober W, Fuss IJ, Blumberg RS. The immunology of mucosal models of inflammation. *Annu Rev Immunol.* 2002;20:495-549.

Strober W, Kelsall B, Fuss I, Marth T, Ludviksson B, Ehrhardt R, et al. Reciprocal IFN-gamma and TGF-beta responses regulate the occurrence of mucosal inflammation. *Immunol Today.* 1997;18:61-64.

Sugiyama T, Tsuchida M, Yokota K, Shimodan M, Asaka M. Improvement of long-standing iron-deficiency anemia in adults after eradication of *Helicobacter pylori* infection. *Int Med* 2002; 41: 491–494.

Summers RW, Elliott DE, Urban JF Jr, Thompson RA, Weinstock JV. Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial. *Gastroenterology* 2005; 128: 825-832.

Sutherland LR, Martin F, Bailey RJ, et al. A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group. *Gastroenterology* 1997; 112:1069- 1077

Sutton CL, Kim J, Yamane A, Dalwadi H, Wei B, Landers C, et al. Identification of a novel bacterial sequence associated with Crohn's disease. *Gastroenterology.* 2000;119:23-31.

Suzuki N, Wakasugi M, Nakaya S, et al. Catalase, a specific antigen in the faeces of human subjects infected with *H. pylori*. *Clin Diagn Laboratory Immunol* 2002; 9: 784–788.

- Sykora J, Hejda V, Varvarovska J, Stozicky F, Gottrand F, Siala K.** *Helicobacter heilmannii* related gastric ulcer in childhood. *J Pediatr Gastroenterol Nutr* 2003;36:410–413.
- Szlachcic A.** The link between *Helicobacter pylori* infection and rosacea. *J Eur Acad Dermatol Venereol* 2002;16:328–333.
- Takahashi M, Kimura H, Watanabe K.** *Helicobacter pylori* infection in patients with idiopathic short stature. *Pediatr Intl* 2002;44:277–280.
- Takashima T, Adachi K, Kawamura A, et al.** Cardiovascular risk factors in subjects with *Helicobacter pylori* infection. *Helicobacter* 2002;7:86–90.
- Talley NJ.** Dyspepsia: how to manage and how to treat. *Alimentary Pharmacology&Therapeutics* 2002; 16:95–104.
- Tamura A, Fujioka T, Nasu M.** Relation of *Helicobacter pylori* infection to plasma vitamin B-12, folic acid, and homocysteine levels in patients who underwent diagnostic coronary arteriography. *Am J Gastroenterol* 2002; 97: 861–866.
- Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, et al.** A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. *N Engl J Med*. 1997;337:1029-1035.
- Timmer A.** Environmental influences on inflammatory bowel disease manifestation. *Digestive Disease* 2003; 21:91- 104
- Truelove SC.** Ulcerative colitis provoked by milk. *Br Med J* 1961; 5220:154-160
- Tsukada Y, Nakamura T, Iimura M, Iizuka BE, Hayashi N.** Cytokine profile in colonic mucosa of ulcerative colitis correlates with disease activity and response to granulocytapheresis. *Am J Gastroenterol*. 2002;97:2820-2828.
- Turnbull RB, Jr, Hawk WA, Weakley FL.** Surgical treatment of toxic megacolon. Ileostomy and colostomy to prepare patients for colectomy. *Am J Surg* 1971; 122:325-331

- Tursi A, Brandimarte G, Giorgetti G, Modeo ME, Gigliobianco A.** Efficacy and tolerability of ranitidine bismuth citrate plus amoxycillin and clarithromycin as first and second line therapy to cure *H. pylori* infection. *Hepatogastroenterol* 2002; 49: 1006–1009.
- Ulrich RMB, Bernhard G, Anett P, Alexandra Z, Thomas W, and Peter M.** Identification of enterohepatic *Helicobacter* species in patients suffering from inflammatory Bowel Disease. *J of Clinical Microbiology* 2004; 42: 2766-2768
- Vaira D, Vakil N, Menegatti M, et al.** The stool antigen test for the detection of *H. pylori* after eradication therapy. *Ann Int Med* 2002; 136: 280–287.
- Vallve M, Vergara M, Gisbert JP, Calvet X.** Single vs. double dose of a PPI in triple therapy for *H. pylori* eradication: a meta analysis. *Alimentary Pharmacology&Therapeutics* 2002; 16: 1149–1156.
- Van Heel DA, Satsangi, J, Carey, AH, Jewell, DP.** Inflammatory bowel disease: progress toward agene.Can *JGastroenterology* 2000; 14:207
- Van Loon S, Bart A, Den Hertog EJ, et al.** *Helicobacter heilmannii* gastritis caused by cat to child transmission. *J Pediatr Gastroenterol Nutr* 2003; 36: 407–409.
- Varanasi RV, Fantry GT, Wilson KT.** Decreased prevalence of *Helicobacter pylori* infection in gastroesophageal reflux disease. *Helicobacter* 1998; 3: 188-194.
- Veneri D, Franchini M, Gottardi MMDA, et al.** Efficacy of *Helicobacter pylori* eradication in raising platelet count in adult patients with idiopathic thrombocytopenic purpura. *Haematologica* 2002; 87: 1177–1179.
- Vicari JJ, Peek RM, Falk GW, et al.** The seroprevalence of cagA-positive *Helicobacter pylori* strains in the spectrum of gastroesophageal reflux disease. *Gastroenterology* 1998; 115: 50-57.

- Viiala CH, Windsor HM, Forbes GM, Chairman SO, Marshall BJ, Millison LC.** Evaluation of a new formulation CLO test. *J Gastroenterol Hepatol* 2002; 17: 127–130.
- Vincent P, Mention K, Leteurtre E, Armand S, Gottrand F.** Absence of *Helicobacter* species in biliary atresia. *Pediatr Infect Dis J* 2003;22:387–388.
- Ward JM, JG Fox, MR Anver, DC Haines, CV George, MJ Collins, PL Gorelick, K Nagashima, MA Gonda, RV Gilden, JG Tully, RJ Russell, RE Benveniste, BJ Paster, FE Dewhirst, JC Donovan, IM Anderson and JM Rice.** Chronic active hepatitis and associated liver tumors in mice caused by a persistent bacterial infection with a novel *Helicobacter* species. *J Natl Cancer Inst* 1994; 86: 1222-1227.
- Ward JM, MR Anver, DC Haines, JM Melhorn, P Gorelick, I Yan and JG Fox.** Inflammatory bowel disease in immunodeficient mice naturally infected with *Helicobacter hepaticus*. *Lab Anim Sci* 1996; 46: 15-20.
- Wemeille J, Cunningham M, Dederdling JP, et al.** Failure of *H. pylori* eradication: is poor compliance the main cause. *Gastroenterol Clin Biol* 2002; 26: 216–219.
- Werdmuller BF, Loffeld RJ.** *Helicobacter pylori* infection has no role in the pathogenesis of reflux esophagitis. *Dig Dis Sci* 1997; 42: 103-105.
- Wexner SD.** General principles of surgery in ulcerative colitis. *Seminars in Gastrointestinal Diseases* 1991; 2:90-106
- Wilder-Smith GH, Wilder Smith P, Grosjean P, et al.** Photoeradication of *H. pylori* using 5 aminolevulinic acid. Preliminary human studies. *Laser Surg Med* 2002; 31: 18–22.
- Won YS, Yoon JH, Lee CH, Kim BH, Hyun BH, Choi YK.** *Helicobacter muricola* sp nov., a novel *Helicobacter* species isolated from the ceca and feces of Korean wild mouse (*Mus musculus molossinus*). *FEMS Microbiol Lett* 2002; 209: 45– 51.
- Wong WM, Wong BC, Xia HH, et al.** An evaluation of a rapid urine test for the diagnosis of *H. pylori* infection in the Chinese

- population. *Alimentary Pharmacology&Therapeutics* 2002; 16: 813–817.
- Xia HH, Wong BC, Wong WM, et al.** Optimal serological tests for the detection of *H. pylori* infection in the Chinese population. *Alimentary Pharmacology&Therapeutics* 2002; 16: 521–526.
- Yagi K, Nakamura A, Sekine A.** Comparison between magnifying endoscopy and histological, culture and urease test findings from the gastric mucosa of the corpus. *Endoscopy* 2002; 34: 376–381.
- Yamada T, RB Sartor, S Marshall RD Specian, and MB Grisham.** Macosal injury and inflammation in a model of chronic gruanulomatous colitis in rats. *Gastroenterology* 1993; 104: 759-771.
- Yee Yk Koo MW, Szeto MI.** Chinese tea consumption and lower risk of *Helicobacter* infection. *J Gastroenterol Hepatol* 2002; 17: 552–555.
- Yoshimura M, Isomoto H, Shikuwa S, et al.** A case of acute gastric mucosal lesions associated with *Helicobacter heilmannii* infection. *Helicobacter* 2002;7:322–326.
- Yu Y, Sitaraman S, Gewirtz AT.** Intestinal epithelial cell regulation of mucosal inflammation. *Immunol Res.* 2004;29:55-68.
- Zentilin P, Seriole B, Dulbecco P, et al.** Eradication of *Helicobacter pylori* may reduce disease severity in rheumatoid arthritis. *Alimentary Pharmacology&Therapeutics* 2002;16:1291–1299.
- Zullo A et al.** *Dig Liver Dis* 2005;37(7);496-500.